Free Trial
→ Collect $7k per month from Tesla’s SECRET dividend (From Investors Alley) (Ad)

AlloVir Q3 2024 Earnings Report

AlloVir logo
$9.63 -0.20 (-2.03%)
As of 02/21/2025 03:59 PM Eastern
Earnings History

AlloVir EPS Results

Actual EPS
-$0.92
Consensus EPS
-$3.22
Beat/Miss
Beat by +$2.30
One Year Ago EPS
N/A

AlloVir Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

AlloVir Announcement Details

Quarter
Q3 2024
Date
11/12/2024
Time
N/A

Conference Call Resources

AlloVir Earnings Headlines

AlloVir, Inc. (NASDAQ:ALVR) Short Interest Down 14.0% in January
February 17, 2025 | americanbankingnews.com
Allovir's general counsel sells $494 in stock
January 28, 2025 | msn.com
Collect $7k per month from Tesla’s SECRET dividend
There's a little-known secret about Tesla that even seasoned investors don't know. Despite not paying a traditional dividend, there's a way to collect up to $7,013 per month from Tesla… starting as early as next month. This backdoor strategy is changing the game for smart investors. Want to see how it works?
February 22, 2025 | Investors Alley (Ad)
Allovir director Vikas Sinha sells $1,225 in stock
January 27, 2025 | msn.com
Allovir's chief accounting officer sells $342 in common stock
January 27, 2025 | msn.com
AlloVir trading halted, news pending
January 16, 2025 | markets.businessinsider.com
See More AlloVir Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like AlloVir? Sign up for Earnings360's daily newsletter to receive timely earnings updates on AlloVir and other key companies, straight to your email.

About AlloVir

AlloVir (NASDAQ:ALVR) engages in the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. It develops novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems. The firm's technology platforms deliver commercially scalable solutions by leveraging off-the-shelf, allogeneic, multi-virus specific T-cells targeting devastating viral pathogens for immunocompromised patients under viral attack. The company was founded by Malcolm K. Brenner, Juan F. Vera, Helen E. Heslop, Cliona M. Rooney, John R. Wilson, and Ann M. Leen in August 2013 and is headquartered in Waltham, MA.

View AlloVir Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles